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INTRODUCTION 
Female Breast cancer was probably the first tumor to be reported in 
history, as early as Egyptian civilisation. Early physicians like 
Hippocrates and Galen described Breast cancer and suggested „black 
bile‟ as the cause of these tumors, which came to be known as 
Humoral theory. In late 17
th
 century, Henry Le Dran , a French 
physician and Claude Nicolas argued that surgical removal was the 
treatment for breast cancer. The importance of axillary nodal 
metatasis was identified since Wilhelm Fabry described axillary 
nodal excision along with primary surgery. 
 
By mid nineteenth century, Sir William Halsted popularised Radical 
Mastectomy as the gold standard treatment for Breast cancers which 
included radical nodal surgery. He popularised that addressing the 
nodes in a radical manner would prevent recurrence and save lives. 
He said that “…breast cancer patients do not do poorly because they 
have regional lymph node metastasis, rather they have these 
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metastasis when they do poorly..” Axillary lymph node dissection as 
an integral part of Mastectomy was unquestioned until the landmark 
NSABP B-04 trial reported in 1977 that addition of axillary 
dissection to Mastectomy does not improve disease free or overall 
survival. Bernard Fischer in 1980 asserted that “… breast cancer is a 
systemic disease, likely at its inception..” and that “…The positive 
lymph node is the reflection of an interrelationship that permits the 
development of metastasis rather than the instigator of distant 
disese…” 
 
Axillary nodal status has long been recognised as one of the 
strongest predictors of breast cancer recurrence and mortality. But 
this is now being challenged in the wake of new clinical trials 
dismissing the role of axillary nodal status in determining the overall 
survival. Added to these are the adverse effects of Axillary 
dissection like Lymphedema, nerve injuries and postoperative 
seroma formation. 
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For the same reasons, there has been a paradigm shift in treatment 
from a radical approach in the axilla to a conservative or minimally 
invasive approach. Advances in Systemic chemotherapy drugs and 
Radiotherapy techniques have complimented this shift in approach.  
 
Recent trends for treatment of axilla in Breast cancer have  
evolved from radical dissection to Sentinel Lymph node biopsy and 
Sentinel Lymph node Dissection. Future of Breast cancer treatment 
lies in personalised treatment for axilla for each individual patient 
based on the tumor characteristics and risk factors. 
 
This study includes Early Breast cancer patients undergoing 
Modified Radical mastectomy and aims  to compare the preoperative 
clinico-radiological axillary staging with pathological staging in 
operated specimens postoperatively and thus to study the precsion 
and accuracy of these preoperative staging modalities. This study 
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also aims to define tumor characteristics like size, grade and 
histology in the patients studied and to relate these to incidence of 
axillary lymph node metastasis in these patients.   
Finally, by studying  these, the feasibility of defining a subgroup in 
early breast cancer patients without any axillary metastasis and to 
study the tumor characteristics and biology in this subgroup will be 
attempted. 
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AIMS & OBJECTIVES:  
1.To compare the preoperative clinico-radiological axillary lymph 
node staging with postoperative histopathological staging and 
determine the accuracy of various staging modalities 
 
 
2. To identify a specific subgroup in early breast cancer patients 
without axillary metastasis and to define the tumor characteristics 
and biology for this subgroup 
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MATERIALS AND METHODS 
PLACE OF STUDY: 
Department of General Surgery, Govt.  Stanley Medical College 
& Hospital,Chennai 
 
DURATION: 
JAN 2014 TO SEP 2015 
 
INCLUSION CRITERIA: 
Patients undergoing Modified Radical Mastectomy for Early 
breast cancerStages Ia,Ib,IIa,IIb 
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EXCLUSION CRITERIA: 
-Patients undergoing        - Breast Conservation Surgery 
         -Neoadjuvant chemotherapy 
         - Recurrent breast cancer 
-Male patients with Breast cancer 
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METHODOLOGY: 
 Patients undergoing Modified Radical Mastectomy for 
Carcinoma Breast in our Department from January 2015 to 
September 2015 are included in this study 
 All patients included in the study were examined after 
admission preoperatively. A detailed clinical history, 
physical examination and radiological investigations were 
done as per the clinical proforma and Evaluation form 
attached at the end.  
 Preoperative Clinical Staging of Breast and Axilla was done 
with TNM staging which was revised after Radiological 
investigations if necessary. 
 The Patient profile was discussed in the Institutional Tumor 
Board, consensus opinion arrived and those patients planned 
for MRM were posted for surgery.  
 Preoperative informed consent was obtained, counselling 
was done to patient regarding the preoperative Diagnosis, 
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Staging workup done, prognosis as per international standard 
for her Stage of the disease, treatment options available for 
her, why surgical management was needed and suggested, 
consequences of non surgical management if she chose it, 
course of treatment after surgery, possible intraoperative and 
postoperative anaesthetic and surgical complications and 
importance of postoperative physiotherapy. The possibility 
of discordance of the preoperative staging and histology with 
postoperative histopathological report was also informed. 
The option of Breast reconstruction at a later date was also 
informed.  
 To avoid bias in the surgical technique, uniform preformed 
and preset protocols were implemented as follows for all 
patients: 
1) All patients were put on overnight fasting for 10 hours as 
per Anaesthetist requirements 
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2) Single dose of Proton Pump Inhibitor (Omeprazole) and 
prokinetic drug (Domperidone) was prescribed for the night 
prior to surgery. No sedative was used. 
3) Early morning preloading with 2 pints  of Normal saline 
and 100 mL of 25% Dextrose at 6am on the day of surgery. 
This was to reduce intraoperative insensible fluid loss due to 
tissue exposure. 
4) Preloading was not done for Diabetic patients, patients at 
high cardiac risk , patients with known End Stage Renal 
Disease.  
5) Short acting Insulin continued till the previous night of 
surgery and Long acting Insulin continued till prior evening 
of surgery for diabetic patients 
6) Long acting anti hypertensives discontinued 24 hours 
prior to surgery. Short acting anti hypertensives continued 
till day of surgery for hypertensive patients. 
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7) Antiplatelet drugs discontinued 7 days prior to surgery 
and other cardiac drugs continued till day of surgery for 
cardiac patients. 
8)Inj.Lignocaine and Inj.Tetanus toxoid prescribed prior to 
surgery along with antibiotic test dose. 
9) Skin preparation with preparation of axilla on the side of 
surgery. 
10) Preoperative single dose of antibiotic half  an hour prior 
to surgery : 
    
for non diabetics – Inj.Ampicillin 2g iv stat 
   for diabetics – Inj.Cefotaxime 1.5 g iv stat 
11) All patients were operated under General Anaesthesia 
with endotracheal Tube. 
12) Patient position – supine posture with sand bag under the 
scapula on the site of surgery with arms hyper abducted to 
100
o. 
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13) Skin prepared with 7.5% Povidone Iodine and draped.  
14) Standard incision extending medially upto sternal edge, 
laterally upto anterior axillary line, and superior and 
inferiorly including skin upto 2.5cm from margin of the 
palpable tumor was made. 
 
15) Flaps were raised in the areolar plane preserving the 
subdermal plexus of vessels superiorly upto the clavicle, 
inferiorly upto submammary fold with Monopolar cautery. 
16) Dissection was done from medial to lateral aspect 
removing the breast tissue along with the Pectoral fascia.  
11) Axillary dissection was done to remove Level I and 
Level II lymph nodes keeping the following structures as 
limits: 
superior- axillary vein 
inferior- Angular vein 
medial- costoclavicular ligament 
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lateral-Thoracodorsal pedicle 
12) Following structures were preserved during Axillary 
dissection: 
-Medial & Lateral Pectoral Nerves 
-Nerve to Latissimus Dorsi 
-Nerve to Serratus Anterior 
-Intercostobrachial Nerves 
-Pectoralis Major & mInor 
13) Flap tacking was done to the chest wall to minimize 
seroma as per positive Institutional study results done 
previously. 
14) 14 size double-suction DT was placed – one limb in the 
superior flap and other in inferior flap.  
15) Postoperatively, the surgeon did a Grossing of the 
specimen – superior border marked with short silk ties, 
lateral border with Long silk ties. Tumor was palpated and 
identified and cut section was made to study the macroscopic 
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features. Axillary nodes were dissected and minimum of 12 
nodes were grossed. The Mastectomy specimen and the 
grossed axillary lymph nodes were sent to Pathologist in 
separate boxes with 40% Formaldehyde as preservative.  
16) Tight Elastoplaster dressings were applied with axillary 
padding. 
17) Oral diet was resumed starting with clear liquids after 3 
hours continuing to semisolid and soft solid diet 
subsequently.  
18) Antibiotics were continued only for Diabetic patients 
postoperatively for 5 days. 
19) All patients were evaluated with DVT risk assessment 
form , categorized and Low Molecular weight Heparin was 
prescribed 0.4mg s.c single dose postop for medium and 
high risk patients. 
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20) First dressing change was done at 48 hours post-op and 
daily dressing done every 24 hours till 5
th
 postoperative day. 
No dressings were applied after 5
th
 post-op day. 
21)DT tubes were kept in situ until drain fluid was less than 
30ml for 3 consecutive days. 
22) Suture removal was done on 7
th
 postoperative day. 
23) Patient was discharged after removal of Drainage tubes 
with advice of regular follow up for review and 
physiotherapy  
Review Protocols: 
First Month – every 2 weeks 
Next 5 months- every 4 weeks 
Next 1 year- every 3 months 
Second year – every 6 months 
After second year - annually 
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23) All patients were referred to Medical Oncology 
department after discharge for Adjuvant chemotherapy. All 
patients undergoing MRM received Adjuvant chemotherapy 
irrespective of the Stage as per Institutional Tumor Board 
Protocol.  
24) Histopathology of the tumor was reported by the 
Pathologist as per College of American Pathologists (CAP) 
Protocol. The same was studied and compared with the 
preoperative clinic-pathological staging and the 
Observations were made and Results arrived at. 
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      Postoperative grossing of specimen 
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        REVIEW OF LITERATURE 
BREAST & AXILLA – RELATED ANATOMY 
 
THE BREASTS 
The breasts are placed in the subcutaneous layer of the thoracic 
wall superficial to Pectoralis Major muscle. They extend 
superiorly from the second rib to sixth rib inferiorly,  medially 
from lateral margin of sternum to anterior axillary line laterally. 
Nulliparous women have a hemispherical breasts, while 
multiparous women have pendulant breasts. The mammary gland 
consists of fifteen to twenty lobes  separated by septa of 
connective tissue and adipose tissue in the subcutaneous layer . 
The mammary tissue is abundant in the upper outer quadrant of 
the breast. The mammary tissue projects towards the axilla as an 
axillary process called tail of Spence .The duct of each lobe, the 
lactiferous duct ,opens separately into the mammary papilla. Each 
lobe is formed by lobules which in turn opens into the main duct. 
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Strands of connective tissue extend from the dermis to the 
Pectoral fascia crossing the breast anteroposteriorly known as the 
Suspensory Ligaments of Cooper. The space between the 
subcutaneous layer and the fascia of the pectoralis major muscle 
is known as the retromammary bursa or also Chassaignac’s bursa 
. This space is responsible for the mobility of the breast on the 
chest wall. On the surface of areola, it has granular and point like 
elevations known as areolar tubercles or Montgomery’s tubercles 
. 
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BLOOD SUPPLY OF THE BREAST 
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THE AXILLA 
It is located between the upper part of the thoracic wall and the 
arm. It is a connecting  passage for the vessels and nerves from 
the neck to the upper limb. Apex is formed by  bones, namely the 
first rib, the upper margin of the scapula and medial part of the 
coracoid process of the scapula, and by the clavicle.  
 
Base is formed by the skin and thick layer of the axillary fascia  
between the pectoralis major muscle which forms the anterior 
axillary fold and the latissimus dorsi which forms the posterior 
axillary fold. The anterior wall is formed by the fibres of 
Pectoralis Major and intermediate portion of Pectoralis Minor. 
Posterior wall is formed by the Subscapularis muscle which 
forms the posterior wall in its upper part and the teres major and 
latissimus dorsi muscles, in its lower part .Medial wall is formed 
by the first four ribs and intercostal muscles and the serratus 
anterior muscle. The Lateral wall is formed by the tendon of the 
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long head of the biceps brachii muscle along with the 
coracobrachialis muscle medially. 
2. Contents of the axilla. The contents of the axilla consist of the 
Axillary artery and its branches, the Axillary vein and its 
tributaries, branches from the Brachial Plexus and finally lymph 
vessels and axillary lymph nodes.  
 
 
 
 
 
 
 
                                     Anatomy of axilla 
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Axillary lymph nodes. The axilla contains several lymph node 
groups. Five axillary lymph node groups are described classically: 
1.Pectoral or Anterior 
2.Subscapular or Posterior 
3.Central 
4. Lateral or humeral 
5.Apical. 
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The axillary lymph nodes are classified into three levels in 
relation with the pectoralis minor muscle. Lymph nodes located 
laterally or below the lower margin of the pectoralis minor 
muscle are classified as level I lymph nodes. The 
pectoral(anterior), subscapular (posterior) and humeral(lateral) 
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are Level I nodes. Lymph nodes located deep to the pectoralis 
minor muscle form the level II lymph nodes and are the central 
lymph nodes and apical nodes. Lymph nodes located medially or 
superiorly to the upper margin of the pectoralis minor muscle 
form the level III lymph nodes, and these are the apical lymph 
nodes . 
 
Through knowledge of anatomy and physiology of the Breast is 
needed for understanding the Natural history and course of 
disease in Breast cancer. What was earlier considered a dreadful 
disease has now become an almost curable malignancy. Research 
into the natural course of the disease combined with advances in 
screening, diagnostic and treatment modalities have resulted in 
this achievement. There has been a drastic rise in the number of 
Breast cancer cases reported. Whether this is a true statistical 
increase or due to the newer screening modalities available is a 
matter of question. What as initially regarded a disease of the 
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socially forward class of the society has now changed its 
distribution to the lower class ,probably due to lack of awareness 
and education among the economically backward sections. Study 
of the disease requires detailed review of its epidemiology. 
 
EPIDEMIOLOGY 
WORLD SCENARIO 
Breast cancer is a global disease. According to World Cancer 
Research fund Statistics 2012 , it is the most common cancer in 
women worldwide with 1.7 million new cases diagnosed in 2012. 
This represents 12% of all new cancer cases and 25 % of all 
cancers in women. Highest incidence of Breast cancer was in 
North America (92 per 100000 population) and Oceania and least 
in Asia and Africa.  
INDIAN SCENARIO 
Though incidence wise Asian countries are at the lower pole, 
there has been a steady increase in the incidence of Breast cancer 
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in Asian countries recently compared to prior reports. India too 
falls in this genre with an increasing incidence. Over 100000 new 
cases are estimated to be diagnosed annually in India 
(Nandakumar,1995; Agarwal et al. 2007). As per ICMR-PBCR 
data,Breast cancer is the commonest cancer among women in 
urban registries of Delhi, Mumbai, Ahmedabad, Kolkata and 
Trivandrum where it constitutes more than 30% of all cancers in 
females( National Cancer Registry Programme, 2001). The age 
standardized Incidence rates (AARs) range from 6.2-39.5 per 
100000 Indian women.  
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The incidence of this disease has been consistently increasing and 
is estimated to have risen by 50% between 1965 and 1985  
( Saxena et al. 2002) .  
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INCREASING INCIDENCE AMONG YOUNG AGE 
 
 
 
The rise in incidence of  0.5-2% per annum has been seen across 
all regions of India and in all age groups but more so in the 
younger age groups (<45years) (Murthy et al. 2007). A significant 
proportion of Indian breast cancer patients are younger than 35 
years of age. This varies from 11% at Tata Memorial Hospital, 
Mumbai (Dinshaw,2006) to 26% at SGPGIMS, Lucknow 
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(Agarwal et al., 2007) Alarming fact is that young age disease has 
been associated with larger tumor size, higher metastatic nodes, 
poorer grades of tumor, poorer overall survival rates. 
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RISK FACTORS FOR BREAST CANCER 
NON MODIFIABLE RISK FACTORS: 
1. GENETIC FACTORS 
Genetic factors are known to be involved in increasing the risk of 
a number of cancers, including breast cancer. A woman’s 
inherited genetic profile impacts her risk   of developing breast 
cancer. Approximately 5-10% of breast cancers are attributable to 
genetic factors. The most common breast cancer susceptibility 
genes are BRCA1, BRCA2, PTEN (Cowden syndrome), and 
TP53 (Li-Fraumeni syndrome). Each child of a parent with a 
mutation has a 50% chance of inheriting the mutation. For 
persons with BRCA1 or BRCA2 mutations, the estimated 
risks   of developing breast cancer by 70 years of age is about 55-
65% (BRAC1) and 45-47% (BRAC2). BRCA1 and BRCA2 
mutations can be inherited from either parent. Genetic testing 
requires both laboratory expertise and genetic counselling 
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services, which are often not available in low-resource settings. 
2. FAMILY HISTORY OF BREAST CANCER: One’s risk of 
developing breast cancer increases with the number of affected 
first-degree relatives. This is thought to be due to a combination 
of factors, both inherited (although not a specific gene) and 
environmental. 
3. PERSONAL HISTORY OF BREAST CANCER: For 
women with a personal history of breast cancer (DCIS or invasive 
breast cancer) there is an increased risk of developing a second 
breast cancer in either the same breast or the opposite breast 
(estimates suggest a 4% increase over 7.5 years). 
4. AGE: Patients above 50 years of age are at increased risk of 
developing Breast cancer especially post menopausal women. 
Cancer in the breast associated with BRCA mutations tend to 
occur at younger age. 
5.SEX:  
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Breast cancer is a common cancer in females and female sex is a 
higher risk for developing Breast cancer. However , when a breast 
lump or malignant nodule develops in the male from mammary 
tissue, it tends to be more aggressive and metastasizes early due 
to lesser amount intervening tissue between the breast and chest 
wall. 
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MODIFIABLE RISK FACTORS:  
1. IONISING RADIATION: Exposure to ionizing therapeutic 
radiation of the chest at a young age (highest risk if exposed at 
10-14 years of age) increases one’s risk; however, the risk of 
developing decreases dramatically if radiation is administered 
after age 40. For example, therapeutic radiation at a young age for 
treatment of Hodgkin lymphoma is associated with an increased 
risk of breast cancer. However, there are no data to suggest that 
current radiation therapy practices administered as part of breast 
cancer treatment, (i.e., radiation therapy after lumpectomy) 
increases the risk for developing a second breast cancer. 
Additionally, mammography and chest x-rays do not appear to 
increase breast cancer risk. 
 
2. HORMONAL AND REPRODUCTIVE FACTORS: 
Endogenous hormones (hormones produced within the body’s 
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cells), particularly estrogen exposure, play a role in breast cell 
growth and proliferation. Elevated or prolonged endogenous 
estrogen levels are associated with an increase risk of breast 
cancer in post-menopausal women. Known risk factors for breast 
cancer are associated with reproductive factors which extend 
natural exposure to hormones produced by the ovaries such as 
early onset of menstruation, late onset of menopause, later age of 
first pregnancy (i.e., over 30 years of age) and never having given 
birth. Laboratory evidence also suggests that higher levels of 
other endogenous hormones, (such as insulin and insulin-like 
growth factor (IGF), may play a role in breast cancer 
development. 
 
3. ESTROGEN HORMONES:  
The use of prolonged hormone replacement therapy (HRT) after 
menopause has been associated with an increased risk of breast 
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cancer. In a large randomized trial, women who took the 
combination of estrogen and progesterone for more than 5 years 
after menopause had an increased risk of being diagnosed with 
breast cancer. It is now recommended that HRT should be used 
only for specific indications (such as significant menopausal 
symptoms) and the duration of treatment should be limited. 
4. WEIGHT (OBESITY): 
An association between obesity and breast cancer risk 
 is thought to be at least partially related to the role of fat cells in  
contributing to levels of circulating hormones and other factors.  
Adiposity (fat cell volume) can affect circulating hormones as  
estrogen precursors are converted to estrogen in fat cells.  
Women’s estrogen levels also vary based on their  
menopausal status, so the effect of obesity on breast cancer risk  
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may depend on the menopausal status of the woman, with post-  
menopausal women being more affected than premenopausal  
women. Some experts suggest that up to 20% of breast cancer  
cases could be avoided by increasing physical activity and  
avoiding weight gain. 
 
 
HISTOLOGICAL TYPES OF BREAST CANCER 
The most common histological type is the Ductal carcinoma, 
followed by lobular carcinomas, and malignancies arising from 
other connective tissues. This list enlists the histological types of 
Breast cancer as per American Joint Committee on Cancer 
(AJCC) classification: 
DUCTAL 
• Intraductal (in situ) 
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• Invasive with predominant intraductal component 
• Invasive, NOS 
• Comedo 
• Inflammatory 
• Medullary with lymphocytic infiltrate 
• Mucinous (colloid) 
• Papillary 
• Scirrhous 
• Tubular 
• Other 
 
LOBULAR 
• In situ 
• Invasive with predominant in situ component 
• Invasive 
 
NIPPLE 
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• Paget's disease, NOS 
• Paget's disease with intraductal carcinoma 
• Paget's disease with invasive ductal carcinoma 
OTHERS 
• Undifferentiated carcinoma 
Histological evaluation of a breast cancer is necessary to provide 
a diagnostic and prognostic picture as well to determine the future 
course of treatment 
BREAST CANCER STAGING 
The American Joint Committee on Cancer (AJCC) staging system 
divides patients into 4 stages according to the TNM system, 
which is based on tumor size (T), lymph node status (N), and 
distant metastasis (M). 
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NOMENCLATURE 
DESCRIPTION STAGE 
In Situ Breast Cancer Stage 0 
Early Invasive Breast Cancer Stage I,IIA,IIB 
Locoregional Breast Cancer Stage IIIA or IIIB 
Metastatic Breast Cancer Stage IV 
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The 5-year survival rates are highly correlated with tumor stage. 
The AJCC staging system correlates well with the prognosis of 
staging groups though it does not take into account other 
associated factors like Tumor grading or histology or Receptor 
status.  
 
Bases on observations, survival rates for each Staging group has 
been assigned as follows: 
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PROGNOSTIC FACTORS 
Several tumour characteristics  that have important prognostic 
significance need to be considered when designing an optimal 
treatment strategy for the individual patient. These are: 
• Age of patient.  
• Tumor size.  
• Axillary lymph node status. This is the most important 
predictor of disease recurrence and survival: 70%–80% of 
patients with node-negative status survive 10 years; 
prognosis worsens as the number of positive lymph nodes 
increases. About 40%–50% of patients with 1 to 3 positive 
nodes survive 10 years, whereas only 15% of those with 
more than 4 nodes survive with surgical treatment alone.  
• Histological grade.  
• Estrogen receptor (ER) and progesterone receptor (PR) 
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status. These are cellular proteins present in hormone-
responsive target tissues. Patients with receptor-positive 
primary tumors have lower rates of recurrence and longer 
survival than those with receptor-negative tumors.  
• HER2-neu(C-erbB2).  
• Tumor suppressor genes p53 and bcl-2 are presently 
considered research tools.  
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MANAGEMENT OF BREAST CANCER 
An integral part of the workup of any case of Breast cancer  
Is Triple assessment. It consists of Clinical Examination,  
Imaging and Tissue sampling as shown. 
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NCCN GUIDELINES FOR MANAGEMENT 
The National Comprehensive Cancer Network is a not for profit 
alliance 26 of world‟s leading cancer centres dedicated improving 
quality, effectiveness and efficacy of cancer care so that patients 
can live better lives. The NCCN Guidelines are a comprehensive 
set of guidelines detailing the sequential management decisions 
and interventions that currently apply to 97% cancers affecting 
patients in United States. NCCN Guidelines provide 
recommendations based on best evidence available at the time 
they are derived. Because new data are published continuously, 
NCCN Guidelines are updated continuously and revised to reflect 
new data and clinical information that may add to or alter current 
clinical practice standards. Hence NCCN Guidelines is a set of 
scientific guidelines which can be followed as it is based on 
evidence based published data. The following are the guidelines 
for the workup and management : 
A. Early Breast cancer 
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B. Locally Advanced Breast Cancer 
C. Metastatic Breast Cancer 
D. Guidelines for Neo-adjuvant/Adjuvant chemotherapy 
E. Guidelines for Adjuvant Hormone Therapy 
F. Guidelines for Adjuvant Radiotherapy 
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A.EARLY BREAST CANCER 
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B.LOCALLY ADVANCED BREAST CANCER 
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C.METASTATIC BREAST CANCER 
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D.ADJUVANT HORMONE THERAPY 
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E.ADJUVANT CHEMOTHERAPY 
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F.ADJUVANT RADIOTHERAPY 
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MANAGEMENT OF AXILLA IN BREAST CANCER – 
CHANGING CONCEPTS 
In the recent decades, the surgical management of axilla has seen 
a drastic change from radical approach to the more conservative 
approach. Initially, a radical axillary dissection was the norm for 
any patient undergoing mastectomy for breast cancer. However, 
with the identification of devastating complication of 
lymphedema and possible nerve injuries during radical axillary 
dissection, there was a gradual shift from radical approach to a 
conservative approach. The landmark trial which paved the 
thought for a conservative approach to axilla was NSABP 04 trial 
started in 1971. It enrolled nearly 1700 women, among them 1079 
were with clinically negative axillary nodes who underwent 
radical mastectomy, total mastectomy without axillary dissection 
but with postoperative radiation or total mastectomy with axillary 
dissection if nodes became clinically positive. It also included 586 
women with clinically positive axillary nodes who underwent 
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radical or total mastectomy, without axillary dissection but with 
postoperative radiation. There no significant survival difference 
among the three groups of women with clinically negative nodes, 
or between those with positive nodes. This absence of survival 
benefit in patients undergoing axillary dissection made 
oncologists think whether the side effects outweigh the benefits in 
an axillary dissection.  
 
With the introduction of the concept of sentinel lymph node by 
Gould et al. in 1960 in a patient with parotid cancer, the 
management protocols for various cancers saw a sea of change. 
Cabanas further did research on sentinel node concept in Penile 
cancer and popularized it. The technique of radiolocalisation 
presently used widely for Breast cancer was pioneered by 
Dr.James C Alex MD, FACS and Dr.David N Krag, MD – 
University of Vermont Medical Centre. Ever since, sentinel 
lymph node biopsy has invited wide research and clinical 
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applications in breast cancer. One of the landmark clinical trials 
was conducted by Veronesi et al. in 2010 presenting the 10 year 
followup of single institute trial to compare outcomes in patients 
who received no axillary dissection with sentinel node was 
negative with patients who received complete axillary dissection. 
The results revealed remarkable advantages in preservation of 
normal axillary nodes with good oncological outcomes. They 
recommended to discard axillary dissection unless the sentinel 
node was positive. From a minimal surgical approach, oncologists 
began to think of offering a multimodality approach to axilla even 
if the sentinel nodes were positive. Thus was conducted the 
EORTC 10981-22023 AMAROS – a randomized, multicenter, 
open label phase 3 non inferiority trial by Mila Donker eta al. 
Early breast cancer patients (T1-2) with no palpable 
lymphadenopathy were included in this study and were allocated 
to receive either axillary lymph node dissection or axillary 
radiotherapy in case of positive sentinel node. The primary end 
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point was non inferiority of 5 year axillary recurrence. It was 
0.4% in axillary lymph node dissection group versus 1.19 % after 
axillary radiotherapy. So this trial suggested comparable 
oncological outcomes for patients treated with axillary dissection 
and axillary radiotherapy after positive sentinel node. These were 
Early breast cancer patients with no palpable lymphadenopathy. 
A trial conducted on similar lines was the National Surgical 
Adjuvant Breast and Bowel Project trial (NSABP-32). It was a 
prospective randomized phase III trial designed to compare the 
oncological outcomes in patients undergoing Sentinel Node 
dissection with those of Axillary dissection in clinically node 
negative patients. 5611 women with operable N0 breast cancer 
were enrolled. At the end of 8 years, there was no significant 
difference in Overall Survival (OS) between patients who 
received Sentinel node dissection with Axillary dissection. There 
was no significant difference in Disease Free survival (DFS) or 
locoregional control between two groups. The results suggested 
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that Sentinel Node dissection should serve as the standard of care 
over Axillary dissection in clinically node negative patients as it 
provides equivalent OS and DFS while minimizing morbidity.  
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OBSERVATIONS  
This study was conducted in Govt. Stanley Medical College & 
Hospital from January 2014 to September 2015. As per the 
methodology already described, the patients coming under 
inclusion criteria were studied and following observations were 
made and results arrived at. 
 
Total number of patients enrolled in study – 40 
The collected patient data were analysed with the help of 
statistical tools. The observations were tabulated, interpreted and 
results were arrived at. The following headers show the criteria 
under which the patient data were categorized and studied. The 
interpretation of these data and results follow. 
 
 
OBSERVATIONAL STATISTICS  
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Table 1. Enrolled patients and their menopausal status 
Stage Number of patients 
Premenopausal 16 
Postmenopausal 24 (19+5) 
 
 
 
 
Natural menopause 19 
Surgical menopause 5 (3+2) 
 
 
TAH alone 3 
TAH with BSO                       2 
 
               Fig.1. Menopausal status of patients under study 
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                         Table 2.Age wise distribution of patients 
 
Fig 2.Age wise distribution of patients in % 
 
 
 
 
 
 
Age group (in years) Number of patients 
20-30 1 
31-40 3 
41-50 17 
51-60 12 
>60 7 
Total 40 
2%
7%
43%30%
18%
Age distribution
20-30
31-40
41-50
51-60
>60
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 Fig.3. Size distribution of tumor as per pT stage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4. Histology of the tumor 
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Table 3. Histology of the tumor under study 
Histology No of patients 
Infiltrating Ductal CA 38 
Invasive Lobular CA 1 
Ductal Carcinoma In situ 1 
 
 
 
 
Infiltrating Ductal 
CA, 38
Invasive Lobular 
Ca, 1
Ductal Carcinoma 
In situ, 1
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No of patients 1 22 8 5 3
0
5
10
15
20
25
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Fig.5 Pathological Nodal status among the patients studied 
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NODAL DISSECTION IN SPECIMEN 
 
Maximum nodes dissected in a specimen : 22 
Minimum nodes dissected in a specimen :  4 
Average number of nodes dissected in a specimen: 13 
 
COMPARATIVE STATISTICS 
I. N stage identified by clinical examination compared with 
N stage identified by Pathological Examination 
 
True Positives (N+ correctly diagnosed as N+) = 12 
True negatives(N0 correctly diagnosed as N0) = 15 
False positives (N0 incorrectly diagnosed as N+) = 9 
False negatives ( N+ incorrectly diagnosed as N0) =4 
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Fig.6 STATISTICAL RATIOS FOR CLINICAL EXAMINATION 
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II. N stage identified by Sonomammogram compared 
with N stage identified by Pathological Examination 
 
True Positives (N+ correctly diagnosed as N+) = 16 
True negatives(N0 correctly diagnosed as N0) = 19 
False positives (N0 incorrectly diagnosed as N+) = 5 
False negatives ( N+ incorrectly diagnosed as N0) =0 
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Fig.7.  STATISTICAL RATIOS FOR SONOMAMMOGRAM 
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Tumor Characteristics in N0 disease 
 
Out of the 40 patients under study, 23 were found to have N0 
disease in histopathology. The following tumor characteristics 
were observed in this subgroup of N0 disease. 
I. Tumor size  
Size & Stage No of patients 
<1 cm 0 
1.1 – 2cm 9 
2.1 – 3cm 6 
3.1 – 4cm 5 
4.1 – 5cm 3 
TOTAL 23 
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Table 4. Tumor size distribution in N0 disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  Fig.8. Tumor size distribution in N0 disease 
 
 
II. Grading of N0 tumors 
 
Grade No of patients 
I 13 
II 9 
III 1 
Total 23 
             Table 5. Tumor size distribution in N0 disease 
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57%
39%
4%
Fig.9. Grade distribution in N0 disease
I II III
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Fig.10. Age distribution in N0 tumors 
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Fig.11. Menopausal status in N0 tumors
IV. Receptor Status in N0 tumors 
 
 
There was a high prevalence of ER positivity and  
 
Her2neu negativity among the 23 N0 tumors studied. 
 
 
16 out of 23 tumors showed an ER positivity whereas only 7 out 
of 23 tumors showed PR positivity. 17 out of 23 tumors showed 
Her2neu negativity.  
 
Status ER PR Her2neu 
Positive 16 7 6 
Negative 7 16 17 
 
                    Table 6. Receptor status in N0 tumors 
 
 
                       V. Menopausal status in N0 tumors 
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RESULTS & SUMMARY 
 
In this study conducted at Govt. Stanley medical College & 
 
Hospital with the described study group, following results  
 
were obtained: 
 
1. There was a higher prevalence of post menopausal subjects 
in the study group constituting 60% of the study group (24 
out of 40 patients). 
 
2. Most of the patients were in the fifth decade of their life 
(41-50 years) constituting 42.5 % of the study group. This 
was the largest age group in the study population. 
 
3. In relation to the tumor size, maximum patients belonged to 
the T1 stage (1.1-2cm) – 15 out of 40 patients constituting 
37.5% of the study group. 
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4. The histology in 95% of tumors were Infiltrating Ductal 
Carcinoma, 2.5 % of the tumors had Invasive Lobular 
Carcinoma and another 2.5% Ductal carcinoma In situ 
 
5. Most of the patients studied had N0 disease – 22 out of 40 
patients (55%); 8 of them (20%) had N1 disease; 5 of them 
(12.5%) had N2 disease; 3 had N3 disease(7.5%), one tumor 
could not be staged due to insufficient nodal dissection. 
 
6. Average number of nodes dissected in a specimen was 13, 
which was in line with the NCCN prescribed guidelines of 
minimum 12 nodes in pathological dissection for accurate N 
staging. 
 
7. On comparing the preoperative axillary lymph node staging 
done by clinical examination and sonomammogram with 
postoperative histopathological staging, Sonomammogram 
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was found to be superior in detecting axillary lymph node 
metastasis compared to clinical examination. 
 Sensitivity and Specificity of Clinical examination was 75% 
and 62.5 % respectively and the Positive predictive value 
was 57.1 % - means if a node is palpated on clinical 
examination , the probability that it is a metastatic node is 
57.1%. Negative predictive value was 78.9% - that is if a 
node is not palpable on clinical examination, there is 78.9% 
possibility that it is an N0 disease.  
 Sensitivity and Specificity of Sonomammogram was 100% 
and 79% respectively and the Positive predictive value was 
76.1%- means if a node is identified on Sonomammogram , 
the probability that it is a metastatic node is 76.1%. 
Negative predictive value was 100% - that is if nodesare not 
seen on Sonomammogram, there is 100% chance that it is 
an N0 disease.  
8. A subset of 23 patients from the total 40 patients       
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studied had N0 disease. Based on observation certain tumor 
characteristics of this subgroup were: 
 Majority of N0 tumors were in T1 stage ( 1.1-2cm) – 
39.1% 
 Most of them were of Grade I ( 13 out of 23) – 56.5% 
 Majority fell in the 5 th decade ( 41-50 years) – 39.1% 
 69.5% of N0 tumors were ER positive and 73.9% were 
her2neu negative. This accounted for the good 
prognosis in this subset.  
 65.2 & (15 out of 23) were postmenopausal patients.  
 
 
CLINICAL IMPLICATION& CONCLUSION 
As discussed in the Literature review, the onus is now on the 
surgeon to adopt a more conservative approach to the axilla in 
Early Breast cancer patients. The aim of this study was to try and 
define few characteristics in N0 subset of patients in Early Breast 
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cancer in whom a conservative approach to axilla could be 
adopted. On concluding this study, the following significant 
characteristics of N0 subgroup of patients could be utilized in 
selecting patients for conservative management of axilla with 
non-radical surgical 
Methods: 
- tumors with T stage T1 or less 
- Grade I tumors 
- ER positive and Her2 neu negative tumors 
- postmenopausal patients 
 
These are in concordance with this study alone, further large 
community based RCTs are required to confirm these results. The 
alternative non radical surgical method can be Sentinel node 
dissection, chemotherapy or Radiotherapy as per the treatment 
guidelines followed by the surgeon and the study results does not 
 93 
include the advantage or disadvantage of any of the described 
modalities. 
 
BIASING FACTORS: 
1. Selection bias - small sample size 
2. Observer bias during histopathological examination 
3. Recall & Response bias-  some patients could not ascertain 
confirmation of details of age and menopausal status.  
4. Digit preference bias – age rounded off by patients to the 
nearest whole number.  
5. Reporting bias – more lenience towards premonitioned 
result and suppression of contradictory facts.  
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 GOVT.STANLEY MEDICAL COLLEGE, CHENNAI- 600 001 
        INFORMED CONSENT 
DISSERTATION TOPIC: “A COMPARATIVE STUDY 
BETWEENPREOPERATIVE AXILLARY LYMPH NODE STATUS 
WITH POSTOPERATIVE HISTOPATHOLOGICAL DIAGNOSIS IN 
OPERABLE CASES OF BREAST CANCER” 
 
PLACE OF STUDY: GOVT. STANLEY MEDICAL COLLEGE, CHENNAI  
NAME AND ADDRESS OF PATIENT: 
I, _____________________ have been informed about the details of the 
study in my own language. 
I have completely understood the details of the study.   I am aware of the 
possible risks and benefits, while taking part in the study. 
I understand that I can withdraw from the study at any point of time and 
even then, I will continue to receive the medical treatment as usual.   I 
understand that I will not get any payment for taking part in this study. 
I will not object if the results of this study are getting published in any 
medical journal, provided my personal identity is not revealed. 
I know what I am supposed to do by taking part in this study and I assure 
that I would extend my full co-operation for this study. 
Name and Address of the Volunteer: 
Signature/Thumb impression of the Volunteer Date: 
Witnesses:(Signature, Name & Address) 
Name and signature of investigator: 
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PROFORMA 
NAME :     AGE /SEX:               IP NO:SL. NO: 
• ADDRESS WITH CONTACT NUMBER:  
• DATE OF ADMISSION 
• HISTORY OF PRESENTING ILLNESS:  
H/O lump in breast 
Onset 
Progression  
Associated symptoms  
Nipple Discharge  
Nipple Retraction  
h/oTrauma  
h/o Fever 
H/o abdominal pain,jaundice 
H/o headache,back pain 
H/o Loss of Weight,Loss of Appettite 
PAST HISTORY: 
Whether a known case of 
DM/hypertension/asthma/TB/epilepsy/cardiac illness 
H/o similar episodes in the past, if any: 
H/o major illness/ hospital admissions, if any:  
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H/o drug intake/contraceptive usage,if any: 
 
PERSONAL HISTORY: 
Age of menarche  
Children 
Breast fed: Yes/No 
menopause: 
FAMILY HISTORY: 
H/o similar complaints in mother,grandmother,female 
siblings,if any  
H/o Prostatic illness in father,if any 
CLINICAL EXAMINATION: 
General examination 
Local Examination:  
Breast and Axilla 
Arm,Chest wall,Supraclavicular fossa  
Systemic examination: 
CVS; RS; CNS; Abdomen; Spine and Cranium 
Clinical diagnosis: 
 
 
 109 
INVESTIGATIONS: 
CBC 
RFT 
HIV 
HBsAg 
Anti-HCV 
Blood Grouping & Typing 
BT/CT: 
Chest X-Ray 
ECG 
USG Breast/Mammogram 
FNAC/Trucut Biopsy 
USG ABDOMEN: 
FINAL DIAGNOSIS: 
 
After MRM, 
Post op HPE reports as per CAP protocol. 
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A COMPARATIVE STUDY BETWEEN 
PREOPERATIVE AXILLARY LYMPH NODE 
STATUS WITH POSTOPERATIVE 
HISTOPATHOLOGICAL DIAGNOSIS IN 
OPERABLE CASES OF BREAST CANCER 
 
 
 
ABSTRACT 
 
Breast cancer is one of the commonest cancers among 
the female population in India. It has a varied spectrum 
spectrum of presentation and when detected early, a 
curative surgery can be offered to the patient. The most 
important prognostic factor determining the local 
recurrence is the axillary lymph node status. 
Management of axilla in Brest cancer has evolved from a 
radical approach to more conservative approaches like 
Sentinel lymph node biopsy. This study encompasses 
patients diagnosed with early Breast cancer upto Stage 
IIb. All these patients were evaluated preoperatively with 
Clinical examination, Sonomammogram and subjected to 
Modified Radical Mastectomy with Adjuvant 
Chemotherapy. Preoperative axillary lymph node status 
were compared with the histopathological staging and 
the sensitivity and specificity of Clinical Breast 
examination and Sonomammogram were calculated and 
the latter was found to be superior. A specific subset of 
population with distinct characteristics in which no 
pathological axillary node metastasis was detected was 
defined. Thus a subgroup ideal for a conservative 
approach to axilla was identified and defined in this 
study.  
 KEYWORDS 
 
Breast cancer 
Axilla 
Sonomammogram 
Mastectomy 
Sentinel node 
